Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | AOC1 | P19801 | 2/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11469461 | 0.72 | — | — | |
| SCHEMBL19361933 | 0.67 | — | — | |
| SCHEMBL543476 | 0.67 | — | — | |
| SCHEMBL11469459 | 0.67 | — | — | |
| SCHEMBL28319712 | 0.65 | — | — | |
| SCHEMBL1997770 | 0.64 | — | — | |
| Cis-Urocanic Acid SCHEMBL1136889 | 0.63 | CYP3A4 (1.00) | HRH3KDM4EBLMNPSR1CYP3A4 | |
| Cis-Urocanic Acid SCHEMBL12963908 | 0.63 | CYP3A4 (1.00) | HRH3KDM4EBLMNPSR1CYP3A4 | |
| Cis-Urocanic Acid SCHEMBL338885 | 0.63 | CYP3A4 (1.00) | HRH3KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL14036942 | 0.62 | ALDH1A1 (0.43) | TSHRMEN1KMT2AMAPTCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841276-B2 | Fulvene and fulvalene analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841276-B2 | Fulvene and fulvalene analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2008137740-A1 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | NOX1, NOX3, ROS1 | HRH3 4290/4885KDM4E 1908/4885BLM 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.